To express the Sense of Congress with respect to safety of medication abortion and Federal preemption of State restrictions on dispensing medication abortion, and for other purposes.
- Sponsor
- Rep. Ryan, Patrick [D-NY-18]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- May 11, 2026
Bottom line
H.R. 8734 is a non-binding resolution declaring medication abortion safe and asserting federal preemption over state-level restrictions on its dispensing and telehealth access.
What it actually does
This bill expresses the Sense of Congress that medication abortion is a safe medical treatment, appropriately approved by the Food and Drug Administration (FDA). Crucially, it states that FDA approval under the Federal Food, Drug, and Cosmetic Act preempts any state laws requiring in-person dispensing by a healthcare practitioner or restricting telehealth for prescribing or dispensing medication abortion. While a Sense of Congress is non-binding, it signals legislative intent regarding federal preemption.
Proponents argue
Supporters argue this bill reaffirms the scientific consensus on the safety and efficacy of medication abortion, as determined by the FDA. They contend that federal regulatory authority, specifically the FDA's approval process, should supersede state-level attempts to restrict access to a federally approved medication, particularly concerning dispensing methods like telehealth, which can improve access for many individuals. Proponents believe this is a necessary step to protect reproductive healthcare access against what they view as medically unnecessary state interference.
Opponents contend
Opponents might argue that this bill oversteps federal authority by attempting to dictate state healthcare policy through a non-binding resolution. They may assert that states have a legitimate interest in regulating medical practices within their borders, including how medications are dispensed, to ensure patient safety, regardless of FDA approval. Critics could also contend that a "Sense of Congress" is an inappropriate mechanism to address complex issues of federalism and healthcare access, especially when it seeks to undermine state laws related to abortion.
The bill text is extremely short and straightforward, allowing for quick comprehension of its explicit statements.
Section 1, paragraphs (1) and (2)
Sense of Congress on Medication Abortion Safety and Federal Preemption
This provision declares that Congress believes medication abortion is a very safe medical treatment, approved correctly by the FDA. It further states that this FDA approval should override any state laws that try to force medication abortion to be dispensed in person by a healthcare provider or that limit its prescription or dispensing through telehealth services. Essentially, it's a statement of congressional opinion on the safety of medication abortion and the supremacy of federal law over state restrictions on its access.
Supporters argue
Supporters argue that this provision is crucial for protecting and expanding access to medication abortion, aligning federal policy with scientific evidence of its safety. They believe it reinforces the FDA's role as the primary authority on drug safety and efficacy, preventing states from imposing medically unnecessary barriers that disproportionately affect rural communities and underserved populations. The statement on preemption is seen as a necessary pushback against state laws that restrict telehealth and in-person dispensing requirements.
Critics contend
Opponents contend that this provision is an overreach of federal power into areas traditionally regulated by states, particularly healthcare practice and public safety. They argue that states have a legitimate interest in regulating how medications, especially those with significant ethical and social implications, are dispensed. Critics may also point out that a "Sense of Congress" is non-binding and therefore an inappropriate way to challenge state laws, potentially creating legal confusion without providing clear statutory guidance.
Tradeoffs
The provision navigates the tension between federal regulatory authority (FDA's drug approval) and states' rights to regulate healthcare within their borders. It also highlights the ongoing debate about access to abortion services versus state-level restrictions, particularly concerning the role of telehealth in medication delivery.